DRT™: The Disease-Relevant Translation™ Platform
Converting emerging knowledge into new therapeutic targets
Proteostasis Therapeutics has assembled a Disease-Relevant Translation (DRT™) platform that combines genomics, proteomics, and functional assays with medicinal chemistry and systems biology to convert the emerging knowledge of the Proteostasis Network (PN) and its function into a tool used to discover novel therapeutics for diseases with huge unmet patient needs.
The DRT™ Platform
Utilizing the DRT™ Platform to discover and develop a new class of drugs that regulate the Proteostasis Network
The DRT™ Platform integrates genomic, proteomic, and functional assay data to generate PN signatures that correlate with efficacy in a particular disease indication. Data contained in these signatures are also used to characterize compound mechanism of action, optimize dosing regimens, and guide patient stratification. Proteostasis Therapeutics is applying the DRT™ platform to identify and validate new therapeutic targets arising from our internal efforts, as well as working with the contributions of our collaborators as part of ongoing relationships to discover novel therapeutics.